These include combining CSF1R inhibitors with immune checkpoint inhibitors, chemotherapy, anti-angiogenic agents, or radiotherapy, aiming to synergistically overcome the immunosuppressive tumor microenvironment (63, 69). Here, CSF1R is linked to neoplasm.